{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:52:43Z","timestamp":1791355963585,"version":"4.3.1"},"reference-count":36,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Innovative Medicines Initiative Joint Undertaking (IMI JU)","award":["115004"],"award-info":[{"award-number":["115004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the impact of a variety of methodological parameters on the association between six drug classes and five key adverse events in multiple databases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The selection of Drug\u2013Adverse Event pairs was based on public health impact, regulatory relevance, and the possibility to study a broad range of methodological issues. Common protocols and data analytical specifications were jointly developed and independently and blindly executed in different databases in Europe with replications in the same and different databases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The association between antibiotics and acute liver injury, benzodiazepines and hip fracture, antidepressants and hip fracture, inhaled long\u2010acting beta2\u2010agonists and acute myocardial infarction was consistent in direction across multiple designs, databases and methods to control for confounding. Some variation in magnitude of the associations was observed depending on design, exposure and outcome definitions, but none of the differences were statistically significant. The association between anti\u2010epileptics and suicidality was inconsistent across the UK CPRD, Danish National registries and the French PGRx system. Calcium channel blockers were not associated with the risk of cancer in the UK CPRD, and this was consistent across different classes of calcium channel blockers, cumulative durations of use up to &gt;10\u2009years and different types of cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A network for observational drug effect studies allowing the execution of common protocols in multiple databases was created. Increased consistency of findings across multiple designs and databases in different countries will increase confidence in findings from observational drug research and benefit\/risk assessment of medicines. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3968","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T17:48:47Z","timestamp":1459705727000},"page":"156-165","source":"Crossref","is-referenced-by-count":41,"title":["Multi\u2010centre, multi\u2010database studies with common protocols: lessons learnt from the IMI PROTECT project"],"prefix":"10.1002","volume":"25","author":[{"given":"Olaf H.","family":"Klungel","sequence":"first","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht University  Utrecht the Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht (UMCU)  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Kurz","sequence":"additional","affiliation":[{"name":"European Medicines Agency (EMA)  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C. H.","family":"de Groot","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht University  Utrecht the Netherlands"},{"name":"Department of Clinical Chemistry and Haematology, Division of Laboratory and Pharmacy University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond G.","family":"Schlienger","sequence":"additional","affiliation":[{"name":"Quantitative Safety and Epidemiology, Novartis Pharma AG  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tcherny\u2010Lessenot","sequence":"additional","affiliation":[{"name":"Global Pharmacovigilance and Epidemiology  Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamiae","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"LA\u2010SER and Pasteur Institute (Pharmacoepidemiology and Infectious Diseases Unit)  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Institut Catal\u00e0 de Farmacologia (FICF)  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf H. H.","family":"Groenwold","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht University  Utrecht the Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht (UMCU)  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Epidemiology Pfizer  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574884708666131111211802"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-9-201011020-00010"},{"issue":"1","key":"e_1_2_7_4_1","first-page":"1","article-title":"The U.S. Food and Drug Administration's Mini\u2010Sentinel program: status and direction","volume":"21","author":"Platt R","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1836"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3846"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3861"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3822"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3816"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3850"},{"key":"e_1_2_7_11_1","unstructured":"SchuerchM GasseC RobinsonNJ et al.Impact of varying definitions of suicidality on the association of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink and Danish national registries. Submitted."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.159"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009147"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3862"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2015.10.007"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000145344.76288.39"},{"issue":"1","key":"e_1_2_7_17_1","first-page":"114","article-title":"Methodological comparison of marginal structural model, time\u2010varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture","volume":"25","author":"Sanni Ali M","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-013-9766-2"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3863"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3860"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000152"},{"key":"e_1_2_7_22_1","unstructured":"AfonsoA SchmiedlS BeckerC et al.Inhaled long\u2010acting beta\u20102\u2010agonists and the risk of acute myocardial infarction: a methodological comparison of two European primary care databases and replication in a US claims database. Submitted."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000436614.51081.2e"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3841"},{"key":"e_1_2_7_25_1","unstructured":"Grimaldi\u2010BensoudaL et al.Long\u2010acting inhaled beta2\u2010agonists and the risk of acute myocardial infarction. submitted."},{"issue":"1","key":"e_1_2_7_26_1","first-page":"1","article-title":"Risk of suicide attempts associated with antiepileptic drugs: a case\u2013control study looking at the effect of differing design options","volume":"22","author":"Grimaldi\u2010Bensouda L","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-143"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00038-014-0564-8"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12358"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt010"},{"issue":"4","key":"e_1_2_7_31_1","first-page":"e134","article-title":"CNODES: the Canadian Network for Observational Drug Effect Studies","volume":"6","author":"Suissa S","year":"2012","journal-title":"Open Med"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11271114"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.01.043"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304738"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3825"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3831"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2003.58.5.003"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3968","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T21:48:52Z","timestamp":1696024132000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":36,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/pds.3968"],"URL":"https:\/\/doi.org\/10.1002\/pds.3968","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}